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OBJECTIVES
§ To define the frequency of incidental findings on low-dose CT 
(LDCT) scans among patients undergoing lung cancer screening.
§ To determine the current reporting methods for incidental findings 
and measure the frequency of clinical follow-up.
RESULTS
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CONCLUSIONS and FUTURE DIRECTIONS
§ Our data demonstrate variability in radiologic reporting of IFs 
detected on screening LDCTs and in clinical follow-up of IFs. 
§ Inconsistent communication of incidental findings and their 
clinical relevance may lead to increased healthcare costs, 
unnecessary radiation exposure and procedures, and/or missed 
opportunity for intervention.
§ Future directions include distribution of standardized guidelines 
for workup of IFs to accompany LDCT reporting to primary care 
providers, followed by reassessment of IF management.
DISCUSSION
§ The occurrence of incidental findings on LDCT for lung cancer 
screening was common, with 75% of screened patients 
demonstrating some degree of CAC (Table 2). Extrathoracic IFs 
included liver, kidney, thyroid, and adrenal glad lesions.
§ Among LDCT scans with extrathoracic IFs, follow-up 
recommendations were included in radiology reports in a minority 
of cases (1.9-17.8%). Specifically, 13 incidental findings warranted 
follow-up by ACR guidelines, but no recommendations were 
reported (Table 3).
§ Patients with severe CAC detected on LDCT for lung cancer 
screening have a high incidence of previously known ASCVD (Table 
4). Patients referred to Cardiology undergo subsequent procedures 
at a significantly higher rate than patients with severe CAC not 
seen by a cardiologist (p<0.001) (Figure 2).
Table 3. Incidental findings and radiologic recommendations for follow-up











n (%) n (%) n (%) n (%)
Stable or benign radiographic 
features noted in report
48 (44.9%) 27 (27.3%) 21 (28.8%) 36 (73.5%)
Follow-up recommendations 
provided in report
2 (1.9%) 5 (5.1%) 13 (17.8%) 1 (2.0%)
No recommendation reported, 
but follow-up indicated by 
ACR guidelines
6 (5.6%) - - 3 (4.1%) 4 (8.2%)










Black or African American 468 (40.1%)
Asian 59 (5.1%)
Other races 6 (0.5%)
BMI, mean ± SD 29.29 ± 6.81
Smoking status, n (%)
Former 527 (45.1%)
Current 641 (54.9%)
Smoking pack-years, mean ± SD 53.68 ± 24.58











Liver findings* 141 (12.1%)
Kidney findings* 108 (9.3%)
Thyroid findings* 86 (7.4%)
Adrenal gland lesions* 49 (4.2%)
*Liver findings included: nodules, cysts, 
calcifications, hemangiomas, steatosis, and 
cirrhosis. Kidney findings included: cysts 
and calculi. Thyroid findings included: 
nodules and thyroid enlargement. Adrenal 
























Management and outcomes among patients with severe CAC
Treated by Cardiologist (n=23)
Not Treated by Cardiologist (n=17)
BACKGROUND
§ The US Preventive Services Task Force (USPSTF) recommends adults 
aged 55-80 with ≥30 pack-year smoking history undergo annual 
screening for lung cancer with a LDCT of the chest.
§ The American College of Radiology (ACR) reports incidental 
detection of liver, kidney, adrenal gland, and thyroid lesions at 
incidences ranging from 3-40%. Among lung cancer screening 
patients, 41–94 % have incidental findings (IFs) on LDCT, and 
coronary artery calcifications (CAC) are the most common IF. CAC is 
an independent predictor of cardiovascular events in post-hoc 
analyses of lung cancer screening cohorts.
§ To our knowledge, there is no standardized approach to radiologic 
reporting or management of IFs on LDCT at Jefferson. Appropriate 
follow-up of IFs has important implications on patient health 
outcomes, healthcare spending, and resource allocation.
METHODS
§ The Jefferson Lung Cancer Screening Program (LCSP) is a 
centralized screening program for patients at high risk for lung 
cancer based on CMS, USPSTF, and NCCN criteria.
§ Data from patients screened between Jan 2018 and February 2020 
were collected prospectively (IRB control# 17D.150).
§ Patients with ≥1 IF reported on LDCT were identified, and radiology 
reports and other clinical data were retrospectively reviewed. 
o For patients with liver, kidney, thyroid, and adrenal gland 
lesions, LDCT reports were reviewed for presence of IF and 
follow-up recommendations and these were compared with 
ACR guidelines.
o A subset of patients with CAC, screened between Jan 2018 and 
April 2019, were reviewed for history of atherosclerotic 
cardiovascular disease (ASCVD), cardiac medications, 
cardiovascular workup, and presence of cardiology evaluation.
1,168 patients were screened between 
Jan 2018 and Feb 2020
384 patients had incidental liver lesions, kidney 
lesions, thyroid lesions, or adrenal gland lesions
427 patients had CAC 
detected on LDCT between 
Jan 2018 – April 2019
Figure 1. CONSORT Diagram. Clinical
data for patients undergoing LDCT for
lung cancer screening were reviewed
for presence of IFs and follow-up.
Table 4. Baseline characteristics of patients with severe CAC detected on LDCT 









Age, y ± SD 67.8 ± 5.6 66.4 ± 3.6 0.318
Sex 0.088
Male, n(%) 10 (43.5%) 12 (70.6%)
Female, n(%) 13 (56.5%) 5 (29.4%)
Race 0.085
White, n(%) 13 (56.5%) 14 (82.4%)
Black, n(%) 10 (43.5%) 3 (17.6%)
Smoking status 0.131
Current smoker, n(%) 15 (65.2%) 7 (41.2%)
Former smoker, n(%) 8 (34.8%) 10 (58.8%)
Cardiovascular history
Known ASCVD#, n(%) 19 (82.6%) 9 (52.9%) 0.043
Patients on statin therapy at baseline, n(%) 21 (91.3%) 14 (82.4%) 0.634
Prior coronary stent or CABG, n(%) 11 (47.8%) 4 (23.5%) 0.117
Patients with a cardiologist prior to LDCT, n(%) 18 (78.3%) 5 (29.4%) 0.002
*within up to 6 months of follow-up time after LDCT
#Atherosclerotic cardiovascular disease (ASCVD) includes: coronary heart disease (angina, MI, HF); 
cerebrovascular disease (CVA/ TIA); peripheral artery disease; aortic atherosclerosis or aortic 
aneurysm
Figure 2. Management, subsequent testing and cardiac events among patients
with severe CAC detected on LDCT (n= 40, Jan 2018-April 2019 cohort).
Patients seen by a cardiologist received medication changes and underwent
additional testing more frequently than those who were not seen by a
cardiologist within 6 months of CAC identification on LDCT.
Clinical data for 328 patients with liver cysts or 
nodules, kidney cysts, thyroid nodules, or adrenal gland 
lesions were reviewed
Clinical data for 40 patients 
with severe CAC were 
reviewed
